Erratum: A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study (Antiviral Therapy (2012) DOI: 10.3851/IMP2443);A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study

Antiviral Therapy

Volumn 17, Issue 7, 2012, Pages 1351-1361

  Bunupuradah, Torsak ^a   Chetchotisakd, Ploenchan ^b   Ananworanich, Jintanat ^a,c,d   Munsakul, Warangkana ^e   Jirajariyavej, Supunnee ^f   Kantipong, Pacharee ^g   Prasithsirikul, Wisit ^h   Sungkanuparph, Somnuek ⁱ   Bowonwatanuwong, Chureeratana ^j   Klinbuayaem, Virat ^k   Kerr, Stephen J ^a,l   Sophonphan, Jiratchaya ^a   Bhakeecheep, Sorakij ^m   Hirschel, Bernard ⁿ   Ruxrungtham, Kiat ^a,d  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^f Taksin Hospital   (Thailand)

^g Chiangrai Prachanukroh Hospital   (Thailand)

^h Bamrasnaradura Infectious Disease Institute   (Thailand)

ⁱ MAHIDOL UNIVERSITY   (Thailand)

^j CHONBURI HOSPITAL   (Thailand)

^k Sanpatong Hospital   (Thailand)

^l UNIVERSITY OF NEW SOUTH WALES   (Australia)

^m National Health Security Office   (Thailand)

ⁿ UNIVERSITY OF GENEVA   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MATRIX; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GASTROINTESTINAL SYMPTOM; GENOTYPE; GENOTYPIC SENSITIVITY SCORE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; THAILAND; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 84867636454     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2452     Document Type: Erratum

References (38)

1. World Health Organization. Antiretroviral therapy of HIV infection in adults and adolescents. Recommendations for a public health approach: 2010 revision. Geneva: World Health Organization 2010.
2. Sungkanuparph S, Anekthananon T, Hiransuthikul N, et al. Guidelines for antiretroviral therapy in HIV-1 infected adults and adolescents: the recommendations of the Thai AIDS Society (TAS) 2008. J Med Assoc Thai 2008; 91:1925-1935.
3. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-1263.
4. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic Ill) 2006; 5:152-156.
5. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44:447-452.
6. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010; 51:496-505.
7. Arribas JR, Delgado R, Arranz A, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 2009; 51:147-152.
8. Campo RE, Lalanne R, Tanner TJ, et al. Lopinavir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS 2005; 19:447-449.
9. Gilks CF, Walker AS, Munderi P, et al. Boosted protease inhibitor monotherapy as maintenance second-line antiretroviral therapy in Africa: a randomised controlled trial (SARA). 18th International AIDS Conference. 18-23 July 2010, Vienna, Austria. Abstract LBPE16.
10. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-291.
11. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
12. Bartlett JA, Aga E, Ribaudo H, et al. Pilot study of LPV/r monotherapy following virologic failure of first-line NNRTI-containing regimens in resource-limited settings: week 24 primary analysis of ACTG 5230. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 583.
13. Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, et al. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors. AIDS 2003; 17:1889-1896.
14. Land S, Cunningham P, Zhou J, et al. TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. J Virol Methods 2009; 159:185-193.
15. Johnson VA, Brun Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010; 18:156-163.
16. Hanna GJ, Johnson VA, Kuritzkes DR, et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J Infect Dis 2000; 181:904-911.
17. National Institute of Allergy and Infectious Disease. Division of AIDS table for grading the severity of adult and pediatric adverse events. (Updated August 2009. Accessed 3 March 2011.) Available from http://rsc.tech-res.com/ Document/safetyandpharmacovigilance/Table-for-Grading-Severity-of-Adult- Pediatric-Adverse-Events.pdf
18. Kerr SJ, Avihingsanon A, Pucharoen O, et al. Assessing adherence in Thai patients taking HAART. Int J STD AIDS 2012; 23:160-165.
19. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med 2006; 354:2473-2483.
20. Puls RL, Srasuebkul P, Petoumenos K, et al. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair Study. Clin Infect Dis 2010; 51:855-864.
21. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333.
22. European AIDS Clinical Society. Clinical management and treatment of HIV infected adults in Europe: version 5. (Updated November 2009. Accessed 3 March 2011.) Available from http://www.europeanaidsclinicalsociety.org/images/stories/ EACS-Pdf/version-5-november2009-eacsguidelines-cologne.pdf
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Updated 27 March 2012. Accessed 3 March 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
24. Perez-Valero I, Arribas JR. Protease inhibitor monotherapy. Curr Opin Infect Dis 2011; 24:7-11.
25. Boger MS, Shintani A, Redhage LA, et al. Highly sensitive C-reactive protein, body mass index, and serum lipids in HIV-infected persons receiving antiretroviral therapy: a longitudinal study. J Acquir Immune Defic Syndr 2009; 52:480-487.
26. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-2374.
27. Randell PA, Jackson AG, Zhong L, Yale K, Moyle GJ. The effect of tenofovir disoproxil fumarate on wholebody insulin sensitivity, lipids and adipokines in healthy volunteers. Antivir Ther 2010; 15:227-233.
28. Pulido F, Perez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther 2009; 14:195-201.
29. Campo RE, Da Silva BA, Cotte L, et al. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses 2009; 25:269-275.
30. Nachega JB, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 2010; 5:70-77.
31. Wei X, Liang C, Gotte M, Wainberg MA. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS 2002; 16:2391-2398.
32. Marcelin AG, Delaugerre C, Wirden M, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.
33. Cozzi-Lepri A, Ruiz L, Loveday C, et al. Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy. Antivir Ther 2005; 10:791-802.
34. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, et al. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. J Infect Dis 2009; 200:687-697.
35. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chantratita W. Mutation pathways of thymidine analogue mutations (TAMs) after virological failure from an initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine. 11th European AIDS Conference. 24-27 October 2007, Madrid, Spain. Abstract P3.4/11.
36. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
37. Ruxrungtham K, Pedro RJ, Latiff GH, et al. Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naive, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227. HIV Med 2008; 9:883-896.
38. A randomised controlled trial to evaluate options for second-line therapy in patients failing a first-line 2 nucleoside reverse transcriptase inhibitors (2NRTI) and nonnucleoside reverse transcriptase inhibitor (NNRTI) regimen in Africa. ISRCTN37737787. (Updated 4 August 2011. Accessed 23 February 2011.) Available from http://controlled-trials.com/ISRCTN37737787/earnest.